He is currently CEO of Hevolution, a first-of-its-kind global organization that provides grants and early-stage investments to incentivize independent research and entrepreneurship to improve human healthspan for the benefit of all humanity. Under his leadership, Hevolution is now the world’s largest philanthropic funder of healthspan science. He was a faculty member in endocrinology at the Mayo Clinic and Medical School, where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also dedicated nine years to leading programs in diabetes, endocrinology, metabolism, and nutrition for the Hennepin County Medical Center, Minneapolis, and University of Minnesota. Dr. Khan is a member of the Board of Directors of International Flavors & Fragrances, the Saudi Research, Development, and Innovation Authority (RDIA), and a member of the Saudi National Biotechnology Strategy Steering Committee. He was the past Chairman of the Visiting Committee on Advanced Technology of the United States’ National Institute of Standards and Technology (NIST), past CEO and Executive Chairman of Life Biosciences, and former board member of Reckitt Benckiser Group PLC and Cormedix. Dr. Khan earned his medical degree from the University of Liverpool School of Medicine, England, and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians in London, a Fellow of the American College of Endocrinology, and an Elected Fellow in the Department of Pharmacology at University of Oxford.